Acadia Pharmaceuticals

Acadia is transforming scientific promise into meaningful innovations. See our community guidelines:

[Acadia Pharmaceuticals @AcadiaPharma]

Today we announced topline results from our Phase 2 RADIANT study of an investigational treatment for Alzheimer's disease psychosis. The results support continuing our Phase 3 program. https://t.co/8dpb86xtVs

[Acadia Pharmaceuticals @AcadiaPharma]

We're heading to @ISCTM's 2026 Autumn Conference, where we'll join the CNS research community to exchange ideas, share insights, and explore what's next in clinical development.

Learn more: https://t.co/r5OieInmHw #ISCTM

[Acadia Pharmaceuticals @AcadiaPharma]

Join us at #PsychCongress2026 in New Orleans as we present our latest data on #ParkinsonsDisease psychosis. We look forward to sharing our latest findings and engaging with the psychopharmacology community.

Learn more and register here: https://t.co/d0B69Rp2FR.

[Acadia Pharmaceuticals @AcadiaPharma]

We're heading to the @CG_Driven 46th Annual Growth Conference where members of our leadership team will discuss Acadia's commitment to advancing innovation for underserved neurological and #raredisease communities.

Learn more: https://t.co/mO1gefZBLG.

[Acadia Pharmaceuticals @AcadiaPharma]

Today, we shared our Q2 2026 #earnings results. Read our $ACAD financial summary and key updates here: https://t.co/3AddrpTuG5.

[Acadia Pharmaceuticals @AcadiaPharma]

Today we announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to our investigational therapy for the treatment of #AlzheimersDisease psychosis (ADP).

Learn more: https://t.co/OzMtk782fF.

[Acadia Pharmaceuticals @AcadiaPharma]

We are pleased to welcome Carl Segerstrom as our new Chief People Officer. Carl will lead Acadia's global people and culture strategy and joins our executive leadership team with more than 25 years of global HR leadership in biopharma.

Learn more: https://t.co/eiDHEYc9ST

[Acadia Pharmaceuticals @AcadiaPharma]

Today, we announced that CHMP has adopted a positive opinion recommending marketing authorization for our treatment for the neurobehavioral symptoms of #RettSyndrome in adults and pediatric patients 5 years and older in the EU.

Learn more: https://t.co/DOCxabpXV6

[Acadia Pharmaceuticals @AcadiaPharma]

We’re looking forward to joining clinicians, researchers, and Rett organizations as we present our latest data in #RettSyndrome at the upcoming @RettSyndrome Scientific Meeting.

Learn more: https://t.co/qrF54mIA1V.

[Acadia Pharmaceuticals @AcadiaPharma]

June is Alzheimer’s & Brain Awareness Month. Founded by the @alzassociation, this month is dedicated to raising awareness about #AlzheimersDisease, a condition that impacts 6M+ Americans.

Discover ways to promote brain health and join the fight: https://t.co/3F5CYRQ1X4. #ENDALZ

[Acadia Pharmaceuticals @AcadiaPharma]

We’re traveling to Washington D.C. this week for the @PMDAlliance #ATMRD2026 Congress where we’ll be sharing our latest findings in #ParkinsonsDisease psychosis and #EssentialTremor. Learn more: https://t.co/KfY5Y7GbcF.

[Acadia Pharmaceuticals @AcadiaPharma]

At Acadia, our purpose extends beyond what we do. It is reflected in how we do it.

We are proud to share our first #CorporateResponsibility Report, highlighting how we support patients, empower our people, and strengthen our communities.

Learn more: https://t.co/ngZZlIrpWS

[Acadia Pharmaceuticals @AcadiaPharma]

We look forward to joining the @ASCPorg annual meeting in Miami as we share our latest findings in Lewy body dementia psychosis and #ParkinsonsDisease psychosis.

Learn more and register here: https://t.co/QE5t6Gt9bu. #ASCP2026

[Acadia Pharmaceuticals @AcadiaPharma]

Heading to the 7th @WorldPDCongress this weekend?

We’re excited to share our latest findings in Lewy body dementia psychosis and #ParkinsonsDisease psychosis while engaging in conversations driving progress for patients. Learn more: https://t.co/gD92saaHaL.

#wpc2026

[Acadia Pharmaceuticals @AcadiaPharma]

We’re proud to bring our latest findings in #RettSyndrome to
#ISPORAnnual this week in Philadelphia. Learn more and register here: https://t.co/GvA0PaJGIh.

[Acadia Pharmaceuticals @AcadiaPharma]

Today, we shared our Q1 2026 #earnings results. Read our $ACAD financial summary and key updates here: https://t.co/lUhkeY15jx.

[Acadia Pharmaceuticals @AcadiaPharma]

We’re looking forward to participating in upcoming #investor conferences, including the @BofA_Business Securities 2026 Health Care Conference and the 2026 @rbccm Capital Markets Global Healthcare Conference.

Learn about our participation: https://t.co/3i4mnkNpCn. $ACAD

[Acadia Pharmaceuticals @AcadiaPharma]

Where neurology comes together.

As #AAN2026 continues, our team is energized by the opportunity to connect with colleagues across the field and engage in thoughtful scientific exchange throughout the meeting.

[Acadia Pharmaceuticals @AcadiaPharma]

At 2026 @AANMember Annual Meeting we’ll be presenting 5 scientific abstracts and posters featuring our latest data and insights from ongoing research efforts in #RettSyndrome, #ParkinsonsDisease, and #EssentialTremor.

Learn more: https://t.co/6qwgM80GDF

[Acadia Pharmaceuticals @AcadiaPharma]

We’re heading to Chicago this weekend for the 2026 @AANMember Annual Meeting.

We’re looking forward to sharing our recent findings in #RettSyndrome, #ParkinsonsDisease, and #EssentialTremor.

Learn more: https://t.co/6Aa1YKZqHn.